Published in J Immunol on March 15, 1988
Properties of the major antigens of rat and human Pneumocystis carinii. Infect Immun (1989) 1.88
Isolation and expression of the Pneumocystis carinii thymidylate synthase gene. Proc Natl Acad Sci U S A (1989) 1.88
Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc Natl Acad Sci U S A (1989) 1.74
Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev (2012) 1.68
Pneumocystis carinii, an opportunist in immunocompromised patients. Clin Microbiol Rev (1991) 1.47
Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice. Infect Immun (1989) 1.43
Identification of Pneumocystis carinii chromosomes and mapping of five genes. Infect Immun (1990) 1.34
Pneumocystis carinii: what is it, exactly? Clin Microbiol Rev (1996) 1.33
Growth and metabolism of Pneumocystis carinii in axenic culture. J Clin Microbiol (1990) 1.28
Purification and characterization of a major human Pneumocystis carinii surface antigen. J Clin Invest (1991) 1.25
Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region. Infect Immun (1998) 1.19
Genetics of surface antigen expression in Pneumocystis carinii. Infect Immun (2001) 1.15
Genome analysis of three Pneumocystis species reveals adaptation mechanisms to life exclusively in mammalian hosts. Nat Commun (2016) 1.13
Development of a rapid real-time PCR assay for quantitation of Pneumocystis carinii f. sp. carinii. J Clin Microbiol (2002) 1.07
Diversity at the locus associated with transcription of a variable surface antigen of Pneumocystis carinii as an index of population structure and dynamics in infected rats. Infect Immun (2003) 1.04
Variation in the major surface glycoprotein genes in Pneumocystis jirovecii. J Infect Dis (2008) 1.03
Gene arrays at Pneumocystis carinii telomeres. Genetics (2005) 1.02
Localization of host immunoglobulin G to the surface of Pneumocystis carinii. Infect Immun (1990) 0.98
Sequencing and characterization of the complete mitochondrial genomes of three Pneumocystis species provide new insights into divergence between human and rodent Pneumocystis. FASEB J (2013) 0.97
Transmission of Pneumocystis carinii from patients to hospital staff. Thorax (1997) 0.97
Proliferative and cytokine responses to a major surface glycoprotein of Pneumocystis carinii. Infect Immun (1993) 0.96
Fungal infections in transplant and oncology patients. Infect Dis Clin North Am (2010) 0.96
Serum titres of Pneumocystis carinii antibody in health care workers caring for patients with AIDS. Thorax (1993) 0.91
Evidence for high prevalence of Pneumocystis jirovecii exposure among Cameroonians. Acta Trop (2009) 0.90
Pneumocystis encodes a functional S-adenosylmethionine synthetase gene. Eukaryot Cell (2007) 0.90
Expression, structure, and location of epitopes of the major surface glycoprotein of Pneumocystis carinii f. sp. carinii. Clin Diagn Lab Immunol (1998) 0.89
Discordant antibody and cellular responses to Pneumocystis major surface glycoprotein variants in mice. BMC Immunol (2012) 0.88
Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis (2004) 0.87
Cellular responses to a 55-kilodalton recombinant Pneumocystis carinii antigen. Infect Immun (1994) 0.86
Pneumocystis carinii and specific fungi have a common epitope, identified by a monoclonal antibody. J Clin Microbiol (1992) 0.86
Identification of a putative precursor to the major surface glycoprotein of Pneumocystis carinii. Infect Immun (1998) 0.84
AIDS and the lung: update 1995. 1. Pneumocystis carinii pneumonia. Thorax (1995) 0.84
The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes. Infect Immun (1997) 0.84
In-vitro interaction of human macrophages with Pneumocystis carinii. Int J Exp Pathol (1991) 0.84
Characterization of the meiosis-specific recombinase Dmc1 of pneumocystis. J Infect Dis (2010) 0.82
Decreased production of local immunoglobulin A to Pneumocystis carinii in bronchoalveolar lavage fluid from human immunodeficiency virus-positive patients. Infect Immun (2000) 0.78
β-Glucans Are Masked but Contribute to Pulmonary Inflammation During Pneumocystis Pneumonia. J Infect Dis (2016) 0.77
Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection. Antimicrob Agents Chemother (1993) 0.77
Development and characterization of a rapid screening assay for identifying antipneumocystis agents. Antimicrob Agents Chemother (1993) 0.76
Pneumocystis encodes a functional endo-β-1,3-glucanase that is expressed exclusively in cysts. J Infect Dis (2014) 0.76
Pneumocystis carinii: A review of an important opportunistic pathogen in AIDS. Can J Infect Dis (1991) 0.75
Preservation of clonal heterogeneity of the Pneumocystis carinii-specific CD4 T cell repertoire in HIV infected, asymptomatic individuals. Clin Exp Immunol (2002) 0.75
Characterization of pneumocystis major surface glycoprotein gene (msg) promoter activity in Saccharomyces cerevisiae. Eukaryot Cell (2013) 0.75
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med (1981) 7.35
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Isolation of a brefeldin A-inhibited guanine nucleotide-exchange protein for ADP ribosylation factor (ARF) 1 and ARF3 that contains a Sec7-like domain. Proc Natl Acad Sci U S A (1996) 5.84
Prospective evaluation of a monoclonal antibody in diagnosis of Pneumocystis carinii pneumonia. Lancet (1986) 5.65
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature (1988) 5.21
Herbal medicines and perioperative care. JAMA (2001) 5.05
The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med (1989) 4.24
Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med (1984) 3.81
Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med (1984) 3.73
Mycobacterium avium-intracellulare: a cause of disseminated life-threatening infection in homosexuals and drug abusers. Ann Intern Med (1982) 3.58
Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA (2001) 3.55
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med (1997) 3.40
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Activation of adenylate cyclase by choleragen. Annu Rev Biochem (1979) 3.16
Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.06
The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med (1975) 3.06
Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med (2001) 3.05
Lysis-filtration blood culture versus conventional blood culture in a bacteremic rabbit model. J Clin Microbiol (1982) 2.98
Hydrolysis of nicotinamide adenine dinucleotide by choleragen and its A protomer: possible role in the activation of adenylate cyclase. Proc Natl Acad Sci U S A (1976) 2.98
The interaction in vitro of Pneumocystis carinii with macrophages and L-cells. J Exp Med (1978) 2.93
Use of lysis-centrifugation (isolator) and radiometric (BACTEC) blood culture systems for the detection of mycobacteremia. J Clin Microbiol (1985) 2.86
The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med (1979) 2.86
Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med (1993) 2.78
Mechanism of action of choleragen. Evidence for ADP-ribosyltransferase activity with arginine as an acceptor. J Biol Chem (1977) 2.76
Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med (1989) 2.69
NIH conference. The acquired immunodeficiency syndrome: an update. Ann Intern Med (1985) 2.68
Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest (1999) 2.65
Pertussis toxin-catalyzed ADP-ribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site. J Biol Chem (1985) 2.64
NIH conference. Gastrointestinal infections in AIDS. Ann Intern Med (1992) 2.62
Studies on the Retention of Hexachlorophene (G-11) in Human Skin. J Bacteriol (1948) 2.54
Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med (1996) 2.50
Serious infections caused by Streptococcus milleri. Am J Med (1978) 2.47
The biotin-dependent enzymes. Adv Enzymol Relat Areas Mol Biol (1971) 2.45
Isolation of human T-lymphotropic virus type III from the tears of a patient with the acquired immunodeficiency syndrome. Lancet (1985) 2.45
Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. Ann Intern Med (1988) 2.42
Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. J Immunol (1982) 2.42
Opportunistic infection in previously healthy women. Initial manifestations of a community-acquired cellular immunodeficiency. Ann Intern Med (1982) 2.41
Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res (2000) 2.37
Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med (1988) 2.33
Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med (1993) 2.32
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest (1983) 2.32
A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest (1985) 2.26
Herpesvirus infections in the acquired immune deficiency syndrome. JAMA (1984) 2.25
Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med (1989) 2.21
Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A (2000) 2.21
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med (1985) 2.18
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
Functional incorporation of ganglioside into intact cells: induction of choleragen responsiveness. Proc Natl Acad Sci U S A (1976) 2.14
Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology (1984) 2.12
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am J Med (1993) 2.11
Monocyte function in the acquired immune deficiency syndrome. Defective chemotaxis. J Clin Invest (1984) 2.10
Rapid, reliable ligation-independent cloning of PCR products using modified plasmid vectors. Biotechniques (1992) 2.09
beta2-Adrenergic receptor regulation by GIT1, a G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein. Proc Natl Acad Sci U S A (1998) 2.08
Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol (2000) 2.07
Activation of adenylate cyclase by heat-labile Escherichia coli enterotoxin. Evidence for ADP-ribosyltransferase activity similar to that of choleragen. J Clin Invest (1978) 2.07
Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates. J Infect Dis (1989) 2.04
Physician staffing in intensive-care units. Lancet (1996) 2.02
Molecular identification of ADP-ribosylation factor mRNAs and their expression in mammalian cells. J Biol Chem (1991) 1.99
Serologic diagnosis of acute lymphadenopathic toxoplasmosis. J Infect Dis (1980) 1.99
Acetyl coenzyme A carboxylase system of Escherichia coli. Purification and properties of the biotin carboxylase, carboxyltransferase, and carboxyl carrier protein components. J Biol Chem (1974) 1.99
Mortality variation across Australia: descriptive data for states and territories, and statistical divisions. Aust N Z J Public Health (2000) 1.98
Acetyl coenzyme A carboxylase. Curr Top Cell Regul (1974) 1.94
The impact of disease severity on the informed consent process in clinical research. Am J Med (1996) 1.94
Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg (1986) 1.93
Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol (2000) 1.93
Detection of Pneumocystis carinii by fluorescent-antibody stain using a combination of three monoclonal antibodies. J Clin Microbiol (1987) 1.90
Risk of nosocomial infection with human T-cell lymphotropic virus type III/lymphadenopathy-associated virus in a large cohort of intensively exposed health care workers. Ann Intern Med (1986) 1.89
Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med (1987) 1.89
The diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage. Am Rev Respir Dis (1984) 1.88
Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med (1989) 1.88
Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest (1989) 1.87
Kaposi's sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome. Ann Intern Med (1985) 1.86
The coronary circulation in human septic shock. Circulation (1986) 1.83
Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis (1996) 1.82
Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem (2000) 1.82
Takayasu's arteritis and its therapy. Ann Intern Med (1985) 1.82
Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites. J Biol Chem (1998) 1.81
Mycobacterium avium-M. intracellulare isolates from patients with or without acquired immunodeficiency syndrome. Antimicrob Agents Chemother (1986) 1.79
Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis (1999) 1.79
Purification and cloning of a brefeldin A-inhibited guanine nucleotide-exchange protein for ADP-ribosylation factors. J Biol Chem (1999) 1.78
Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med (1986) 1.77
Rating long-term care facilities on pressure ulcer development: importance of case-mix adjustment. Ann Intern Med (1996) 1.75
Activation of rat brain phospholipase D by ADP-ribosylation factors 1,5, and 6: separation of ADP-ribosylation factor-dependent and oleate-dependent enzymes. Proc Natl Acad Sci U S A (1994) 1.74
Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of Bordetella pertussis toxin (islet-activating protein). J Biol Chem (1983) 1.74
Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev (2011) 1.73
Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. Am J Hosp Pharm (1979) 1.72
Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med (1987) 1.70